Pár Gabriella, Berki Tímea, Pálinkás László, Balogh Péter, Szereday László, Halász Melinda, Szekeres-Barthó Júlia, Miseta Attila, Hegedus Géza, Mózsik Gyula, Hunyady Béla, Pár Alajos
Pécs Tudományegyetem, Altalános Orvostudományi Kar, I. Belgyógyászati Klinika.
Orv Hetil. 2006 Apr 2;147(13):591-600.
The outcome of HCV infection and the response to antiviral treatment depend on both viral and host factors. Host immune response contributes not only to viral control, clinical recovery and protective immunity, but also to chronic hepatitis and liver cirrhosis. Establishing immunological status and identifying pretreatment immunological factors associated with better response to therapy might be of importance in the understanding of the successful immune response and in the future of combination therapy to HCV infection.
The authors delivered a review on the immunology of HCV infection and characterized the cause of impaired cellular immune response in chronic HCV infection. Natural killer (NK) cell activity, perforin and the inhibitory CD81 HCV co-receptor expression, and Th1/Th2 cytokine production of the monocytes and lymphocytes have been investigated.
42 patients with chronic hepatitis C, out of them 25 being on interferon (PEG-IFN) + ribavirin (RBV) therapy, 12 sustained virological responders, 26 HCV carriers with normal transaminase values and 22 healthy controls were studied. NK cell activity, perforin and CD81 expression, the IFNgamma, TNFalpha, IL-2 (Th1) and IL-4, IL-6, IL-10 (Th2) production of LPS stimulated monocytes and PMA + ionomycine stimulated lymphocytes were measured by flow-cytometry.
In patients with chronic hepatitis C we demonstrated decreased NK cell activity associated with increased CD81 expression. The perforin expression of lymphocytes was also impaired in HCV patients. The pretreatment capacity of the macrophages to produce TNFalpha was predictive for sustained virological response. This increased TNFalpha production of the monocytes counteracted the observed impaired Th1 type cytokine production of the lymphocytes. IL-10 and IL-4 production showed positive correlation with HCV RNA levels, and negative correlation with histological activity index was noted. PEG-IFN + RBV treatment increased NK activity, perforin expression, Th1 type cytokine production of thr lymphocytes and downregulated CD81 expression inducing effective cellular immune response against HCV. The author's results provide further data to understand the causes of impaired cellular immune response in chronic HCV hepatitis and may be useful in the developement of immunotherapy as an adjunctive treatment to cure patients with chronic hepatitis C.
丙型肝炎病毒(HCV)感染的结果以及对抗病毒治疗的反应取决于病毒和宿主因素。宿主免疫反应不仅有助于病毒控制、临床康复和保护性免疫,还与慢性肝炎和肝硬化有关。确定免疫状态并识别与更好治疗反应相关的治疗前免疫因素,对于理解成功的免疫反应以及未来HCV感染联合治疗的发展可能具有重要意义。
作者对HCV感染的免疫学进行了综述,并阐述了慢性HCV感染中细胞免疫反应受损的原因。研究了自然杀伤(NK)细胞活性、穿孔素和抑制性CD81 HCV共受体表达,以及单核细胞和淋巴细胞的Th1/Th2细胞因子产生情况。
研究了42例慢性丙型肝炎患者,其中25例接受聚乙二醇干扰素(PEG-IFN)+利巴韦林(RBV)治疗,12例为持续病毒学应答者,26例丙氨酸转氨酶值正常的HCV携带者以及22名健康对照者。通过流式细胞术测量NK细胞活性、穿孔素和CD81表达,以及脂多糖刺激的单核细胞和佛波酯+离子霉素刺激的淋巴细胞产生的干扰素γ、肿瘤坏死因子α、白细胞介素-2(Th1)和白细胞介素-4、白细胞介素-6、白细胞介素-10(Th2)。
在慢性丙型肝炎患者中,我们发现NK细胞活性降低与CD81表达增加有关。HCV患者淋巴细胞的穿孔素表达也受损。巨噬细胞产生肿瘤坏死因子α的治疗前能力可预测持续病毒学应答。单核细胞增加的肿瘤坏死因子α产生抵消了观察到的淋巴细胞Th1型细胞因子产生受损的情况。白细胞介素-10和白细胞介素-4的产生与HCV RNA水平呈正相关,与组织学活动指数呈负相关。PEG-IFN + RBV治疗可增加NK活性、穿孔素表达、淋巴细胞的Th1型细胞因子产生,并下调CD81表达,诱导针对HCV的有效细胞免疫反应。作者的结果为理解慢性HCV肝炎中细胞免疫反应受损的原因提供了进一步的数据,可能有助于开发免疫疗法作为治疗慢性丙型肝炎患者的辅助治疗方法。